Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA; Department of Liver Surgery, Ren Ji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA; Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
J Hepatol. 2019 Oct;71(4):719-730. doi: 10.1016/j.jhep.2019.05.029. Epub 2019 Jun 13.
BACKGROUND & AIMS: Hepatic ischemia-reperfusion injury (IRI) is a major complication of hemorrhagic shock, liver resection and transplantation. YAP, a key downstream effector of the Hippo pathway, is essential for determining cell fate and maintaining homeostasis in the liver. We aimed to elucidate its role in IRI.
The role of YAP/Hippo signaling was systematically studied in biopsy specimens from 60 patients after orthotopic liver transplantation (OLT), and in a mouse model of liver warm IRI. Human biopsy specimens were collected after 2-10 h of cold storage and 3 h post-reperfusion, before being screened by western blot. In the mouse model, the role of YAP was probed by activating or inhibiting YAP prior to ischemia-reperfusion.
In human biopsies, high post-OLT YAP expression was correlated with well-preserved histology and improved hepatocellular function at postoperative day 1-7. In mice, the ischemia insult (90 min) triggered intrinsic hepatic YAP expression, which peaked at 1-6 h of reperfusion. Activation of YAP protected the liver against IR-stress, by promoting regenerative and anti-oxidative gene induction, while diminishing oxidative stress, necrosis/apoptosis and the innate inflammatory response. Inhibition of YAP aggravated hepatic IRI and suppressed repair/anti-oxidative genes. In mouse hepatocyte cultures, activating YAP prevented hypoxia-reoxygenation induced stress. Interestingly, YAP activation suppressed extracellular matrix synthesis and diminished hepatic stellate cell (HSC) activation, whereas YAP inhibition significantly delayed hepatic repair, potentiated HSC activation, and enhanced liver fibrosis at 7 days post-IRI. Notably, YAP activation failed to protect Nrf2-deficient livers against IR-mediated damage, leading to extensive fibrosis.
Our novel findings document the crucial role of YAP in IR-mediated hepatocellular damage and liver fibrogenesis, providing evidence of a potential therapeutic target for the management of sterile liver inflammation in transplant recipients.
In the clinical arm, graft YAP expression negatively correlated with liver function and tissue damage after human liver transplantation. YAP activation attenuated hepatocellular oxidative stress and diminished the innate immune response in mouse livers following ischemia-reperfusion injury. In the mouse model, YAP inhibited hepatic stellate cell activation, and abolished injury-mediated fibrogenesis up to 7 days after the ischemic insult.
肝缺血再灌注损伤(IRI)是失血性休克、肝切除和肝移植的主要并发症。YAP 是 Hippo 通路的关键下游效应物,对于确定细胞命运和维持肝脏内稳态至关重要。我们旨在阐明其在 IRI 中的作用。
我们系统研究了 YAP/Hippo 信号通路在 60 例原位肝移植(OLT)患者肝活检标本和肝脏热IRI 小鼠模型中的作用。在冷保存 2-10 小时和再灌注后 3 小时收集人活检标本,然后通过 Western blot 进行筛选。在小鼠模型中,通过在缺血再灌注前激活或抑制 YAP 来探究 YAP 的作用。
在人类活检标本中,OLT 后 YAP 高表达与术后 1-7 天保存完好的组织学和改善的肝细胞功能相关。在小鼠中,缺血损伤(90 分钟)触发了内在的肝 YAP 表达,在再灌注 1-6 小时达到峰值。激活 YAP 通过促进再生和抗氧化基因的诱导,减少氧化应激、坏死/凋亡和固有炎症反应,从而保护肝脏免受 IR 应激。抑制 YAP 加重肝 IRI 并抑制修复/抗氧化基因。在小鼠肝细胞培养物中,激活 YAP 可防止缺氧再氧合诱导的应激。有趣的是,YAP 激活抑制细胞外基质合成并减少肝星状细胞(HSC)激活,而 YAP 抑制则显著延迟肝修复,增强 HSC 激活,并在 IRI 后 7 天增强肝纤维化。值得注意的是,YAP 激活未能保护 Nrf2 缺陷肝脏免受 IR 介导的损伤,导致广泛纤维化。
我们的新发现证明了 YAP 在 IR 介导的肝细胞损伤和肝纤维化中的关键作用,为管理移植受者无菌性肝炎症提供了潜在的治疗靶点。
临床方面,供体 YAP 表达与人类肝移植后肝功能和组织损伤呈负相关。YAP 激活可减轻小鼠肝脏缺血再灌注损伤后的肝细胞氧化应激并减少固有免疫反应。在小鼠模型中,YAP 抑制肝星状细胞激活,并在缺血性损伤后 7 天内消除损伤介导的纤维化。